Michael Berman

Picture of Michael Berman
Professor Emeritus, Obstetrics & Gynecology
School of Medicine
M.D., George Washington University
Phone: (714) 456-8020
Email: mberman@uci.edu
University of California, Irvine
333 City Blvd West
Suite 1400
Orange, CA 92868
Research Interests
Gynecologic Oncology
Research Abstract
CLINICAL INTERESTS

Dr. Berman is interested in improving the management of women with gynecologic cancers and those with complex gynecologic surgical conditions. He is widely recognized as a leader in this field having developed new surgical procedures for a variety of complex gynecologic conditions. He is listed in the August 1997 Good Housekeeping Magazine as among the 401 "Best Doctors for Women in the U.S." and in The Best Doctors in America: Pacific Region,1st Edition, Woodward/White, Inc., 1997.

RESEARCH INTERESTS

With others in the Gynecologic Oncology Program at UCI, Dr. Berman participates in a wide range of multi-institutional protocol studies under the direction and support of the National Cancer Institute (NCI). Dr. Berman has conducted an epidemiologic study of endometrial cancer to elucidate risk factors, including obesity, diet, gynecologic history, exposure to exogenous hormone, tobacco, and alcohol associated with endometrial cancer and gestational trophoblastic diseases.

In the area of cancer prevention, he has been principal investigator of an NCI-funded, phase II/III clinical trial of beta-carotene in the treatment of pre-invasive cervical disease (CIN II & III). This study followed up on preliminary work performed at the UCI Medical Center suggesting that this vitamin derivative may be a therapeutic agent for the treatment of preinvasive cancer of the cervix. This study will help determine whether beta-carotene will effect regression of CIN. Additional questions which will be addressed by this study include how infection with various human papilloma virus strains may alter the effects of beta-carotene on the regression of CIN.

An additional point of investigation concerns the possible influence of tissue and serum levels of beta-carotene and vitamin A on response to therapy. Cervical cancer represents the leading cause of cancer mortality in women in many Third World countries. If beta-carotene can cause regression of premalignant conditions in the cervix, the implications for women in the underdeveloped countries who are at high risk for this diagnosis are quite far reaching. The results of this study may have a major impact on dietary practices and the use of vitamin supplements throughout the world.
Publications
Im SM, Gordon AN, Buttin BM, Leath, III CA, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML. Validation of referral guidelines for women with pelvic mass. Obstet & Gynecol, 105:1 1-7. January 2005.
Chan, JK, Loizzi V, Magistris A, Lin F, Rutgers J, Osann K, DiSaia PJ, Berman ML. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. Clinical Cancer Research. Vol. 10, Dec. 15, 2004.
Lacey Jr. JV, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, Sherman ME, and Brinton LA. Insulin-Like Growth Factors, Insulin-Like Growth Factor-Binding Proteins, and Endometrial Cancer in Postmenopausal Women: Results from a U.S. Case-Control Study. Cancer Epidemiol Biomarkers & Prev, 13(4), 2004.
Geas FL, Rutgers JKL, Tewari KS, Berman ML. Surgical Cytoreduction and Hormone Therapy of an Advanced Endometrial Stromal Sarcoma of the Ovary. Obstetrics & Gynecology, 103(5 Pt 2): 1051-1054, 2004.
Berman, ML. Adjuvant radiotherapy following properly staged endometrial cancer: what role? Gynecol Oncol, 92(3): 737-39, 2004
Chan JK, Loizzi V, Manetta A, Berman ML. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol, 92: 368-71, 2004.
Chan JK, Monk B J, Upasani S, McHale M, Keefe K, Brewer C, McMeekin R, Rose S, Wilczynski S, Meyskens F, Berman ML. Factors that influence the regression of CIN in a randomized, placebo, controlled beta carotene trial. British Journal of Cancer (2003) 89, 1062 -1066.
Fruehauf JP, Tewari KS, Burger RA, Mehta RS, Yu IR, Monk BJ, Manetta AM, Berman ML, DiSaia PJ. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Cancer, Oct 2003.
Lacey J, Potischman N, Madigan M, Berman ML, Mortel R, Twiggs L, Barrett R, Wilbanks G, Lurain J, Filmore C, Sherman M, Brinton L. Insulin-like growth factor binding proteins, and endometrial cancer: results from a U.S. case-control study. Am J of Obstet & Gynecol, May 2003.
Chan JK, Monk BJ, Brewer C, Keefe KA, Osann K, McMeekin S, Rose GS, Youssef M, Wilczynski SP, Meyskens FL, Berman ML. HPV infection and number of lifetime sexual partners are strong predictors for ‘natural’ regression of CIN 2 and 3. British Journal of Cancer, 89 (6), 1062-1066, 2003.
Chan JK, Lin YG, Loizzi VL, Ghobriel M, DiSia PJ, Berman, ML. Fertility-sparing surgery and outcome of reproductive age women with epithelial ovarian borderline tumors. Submitted to The Journal of Reproductive Medicine, 48:756-60, 2003.
Berman ML, Truong TH, BS, DiSaia PJ, Chan JK. Modified technique for suprapubic catheter insertion that avoids urinary leakage. Am J Obstet and Gynecol, Oct 2003.
Berman, ML. Future directions in the surgical management of ovarian cancer. Gynecol Oncol 90(2 Pt 2): S33-9, 2003. Review.
Berg J, Tewari KS, Del Rosario R, Berman ML. Unusual presentation of a malignant granular cell tumor of the pelvis: case report and literature review. Gynecol Oncol 90(1):224-30, 2003. Review.
Chan JK, Loizzi V, Magistris A, Lin F, Rutgers J, Osann K, DiSaia PJ, Berman ML. The significance of molecular marker in survival of young women with advanced ovarian cancer. Obstetrics and Gynecology. Jun 2003.
Chan JK, Loizzi V, Magistris A, Lin F, Rutgers J, Osann K, DiSaia PJ, Berman ML. The significance of molecular marker in survival of young women with advanced ovarian cancer. Clinical Cancer Research. Jun 2003.
Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay – guided chemotherapy. Am J Obstet Gynecol. 189(5):1301-7, 2003.
Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev S, Berman ML. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 90(1): 181-5, 2003.
Chan JK, Monk BJ, Brewer C, Keefe KA, Osann K, McMeekin DS, Rose GS, Youssef M, Wilszynski SP, Meyskens FL, Berman ML. HPV infection and number of lifetime sexual partners are strong predictors for ‘natural’ regression of CIN 2 and 3. B J Cancer 89(6):1062-1066, 2003.
McHale MT, Berman ML, Keefe K, Schell M, Peng YM, Monk BJ. Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3. Journal of Lower Genital Tract Disease 6(4):220-224, 2002
Berman ML. SGO Presidential Address. Society of Gynecologic Oncologists. Gynecol Oncol 86(2):107-114, 2002.
Loizzi V, Cappuccini F, Berman ML. An unusual presentation of struma ovarii mimicking a malignant process. Obstet and Gynecol 100(5 Pt 2): 1111-1112, 2002.
Berman, ML. Advances in cervical cancer management from North American Cooperative Group Clinical Trials. Yonsei Medical Journal 43(6): 729-736, 2002. Review.
Syed AM, Puthawala AA, Abdelaziz NN, El-Naggar M, DiSaia PJ, Berman ML, Tewari KS, Sharma A, Londrc A, Juwadi S, Cherlow J, Damore S, Chen Y. Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiation Oncology Biol Phys 54(1):67-78, 2002.
Chan JK, Youssef M., McMeekin S, Monk, BJ, Osann K, Vasilev S, DiSaia, PJ, Berman ML. Survival outcomes of uterine papillary serous carcinoma after cytoreductive surgery and taxol and platinum-based chemotherapy. Gynecol Oncol 83:161, 2001.
Keefe KA, Schell MJ, Brewer C, McHale MT, Brewster WR, Chapman JA, Rose GS, McMeekin DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML. A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high grade cervical intraepithelial neoplasia. Cancer Epidemiology, Biomarkers & Prevention 10(10):1029-1035, 2001.
Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD, Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 97(5 pt 1):707-11, 2001.
Palmer JR, Driscoll SG, Rosenberg L, Berkowitz RS, Lurain JR, Soper J, Twiggs LB, Gershenson DM, Kohorn EI, Berman ML, Shapiro S, Rao S. Oral contraceptive use and risk of gestational trophoblastic tumors. J Natl Cancer Inst, 91: 635-39, Apr 1999.
Tewari K, Cappuccini F, Syed AM, Puthawala A, DiSaia PJ, Berman ML, Manetta A, Monk BJ. Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer. Am J Obstet Gynecol, 181(1): 91-98, Jul 1999.
Tewari K, Cappuccini F, Brewster WR, DiSaia PJ, Berman ML, Manetta A, Puthawala A. Interstitial brachytherapy for vaginal recurrences of endometrial cancer. Gynecol Oncol 74: 416-422, Aug 1999.
Tewari K, Cappuccini F, DiSaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol 95: (1)128-133, Jan 2000.
Lacey JV, Brinton LA, Mortel R, Berman ML, Wilbanks GD, Twiggs LB, Barrett RJ. Tubal sterilization and risk of cancer of the endometrium. Gynecol Oncol 79: 482-484, 2000.
Tewari K, Cappuccini F, Puthawala A, Kuo J, Burger RA, Monk BJ, Manetta A, Berman ML, DiSaia PJ, Syed AM. Primary evasive carcinoma of the vagina: Treatment with interstitial brachytherapy. Cancer 91(4):758-770, Feb 2001.
Professional Societies
Society of Gynecologic Oncologists
Am. College of Ob/Gyn
American College of Surgery
Last updated
01/04/2018